Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony zgody na udział w badaniu
- •Rozpoznany histologicznie klasyczny chłoniak Hodgkina
- •Nawrotowa choroba lub brak odpowiedzi na leczenie po maksymalnie 1 linii wcześniejszego leczenia
- •Powinien mieć zmianę widoczną w badaniu obrazowym (najmniejszy rozmiar 1,5 cm)
- •Liczba neutrofili w krwi co najmniej 1000/mm³
- •Liczba płytek krwi co najmniej 50 000/mm³
- •Nie może być kandydatem do przeszczepienia szpiku kostnego ze względu na wiek, stan zdrowia lub preferencje
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
City of Hope Medical Center
Duarte, United States
University of Chicago Cancer Research Center
Chicago, United States
Dana-Farber Cancer Institute
Boston, United States
Hackensack University Medical Center/John Theurer Cancer Center
Hackensack, United States
Sarah Cannon Research Institute
Nashville, United States
Trial contact
Alex Herrera, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.